Clinical Study of Transcriptome-based Diagnostic Biomarker for Acute Febrile Illness
NCT ID: NCT06552975
Last Updated: 2024-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
900 participants
OBSERVATIONAL
2021-09-01
2025-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Transcriptomic Responses for the Identification of Pathogens
NCT04878549
AI-Guided Proteomic Biomarker Panel for Differentiating Bacterial and Viral Infections in Acute Febrile Illness
NCT07205575
Promotion and Application of a New Three-level Etiological Diagnosis Strategy for Fever Clinics in Respiratory Infectious Diseases
NCT05965128
A Validation Study on a Prognostic Prediction Model for Respiratory Tract Infections
NCT07109310
Early Identification and Severity Prediction of Acute Respiratory Infectious Disease
NCT04955756
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Furthermore, the misuse of antibacterial drugs in patients with non-bacterial infections can lead to complications such as secondary infections with Clostridium difficile, liver dysfunction, kidney damage, cytopenia, and alterations in the body's microbiota. Diagnostic markers based on host inflammatory responses offer an alternative approach to infection diagnosis. However, protein biomarkers like procalcitonin, though widely used in clinical settings, are far from ideal for accurately diagnosing bacterial infections, as they are prone to false positives and negatives.
A promising direction is the analysis of host-pathogen interactions at the transcriptome level, particularly the differential gene expression of the host in response to various pathogens. This area of research has gained significant attention recently. Transcriptomic markers derived from patients' peripheral blood have been successfully utilized in diagnosing and studying the pathogenesis of various infectious diseases.
Despite these advances, studies relying on RNA sequencing or transcriptome chip technology require specialized equipment and bioinformatics expertise, making them expensive and challenging to implement in routine clinical practice. Additionally, the results from transcriptome analysis are not easily validated by reverse transcription polymerase chain reaction(RT-PCR), the "gold standard" for RNA quantification. Therefore, to make transcriptome-based diagnostic markers more clinically applicable, there is a need for real-time technologies, such as PCR, to enhance the accuracy of infection diagnosis and reduce the misuse of antibacterial drugs. Currently, research in this area remains limited.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bacterial infection
Individuals with acute fever whose positive bacteria isolated from sterile or non-sterile sites have pathological characteristics.
Infection
Pathogens such as bacteria and viruses invade the human body, grow, and proliferation, triggering an immune response.
Viral infection
Individuals with acute fever whose viral nucleic acid test and/or serological positive compatible with acute syndrome#(e.g. serology, PCR).
Infection
Pathogens such as bacteria and viruses invade the human body, grow, and proliferation, triggering an immune response.
non-infectious group
Individuals with acute fever whose have negative findings in cultures and PCR; negative image modality findings suspected for infection; confirmed or highly likely other diagnosis; improvement without antibiotics.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Infection
Pathogens such as bacteria and viruses invade the human body, grow, and proliferation, triggering an immune response.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
14 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qilu Hospital of Shandong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gang Wang
Role: STUDY_DIRECTOR
Qilu Hospital of Shandong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Qilu Hospital of Shandong University
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Gang Wang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KYLL-202008-058
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.